文献速递妇科

加利福尼亚州宫颈癌患者近距离放疗利用不足及生存差异

Underutilization of brachytherapy and disparities in survival for patients with cervical cancer in California.
PubMed 文献 · Gynecol Oncol · 2018-04-27

基于加州癌症登记处2004至2014年4783例FIGO IB2-IVA期宫颈癌患者,分析近距离放疗(BT)使用趋势及生存差异。45%患者接受BT,18%接受外照射推量,37%未接受推量;BT使用与更好的病因特异生存和总生存相关,黑人患者和低社会经济地位患者病因特异生存更差。

要点

  • 局部晚期宫颈癌中仅45%接受近距离放疗,18%接受外照射推量,37%未接受推量。
  • 使用BT与改善的病因特异生存(HR 1.16,p=0.0330)和总生存(HR 1.14,p=0.0333)相关。
  • 黑人患者和低社会经济地位患者病因特异生存更差。

核心结论

  • 局部晚期宫颈癌近距离放疗使用率低至45%,且与病因特异生存和总生存下降相关。
  • 黑人患者和低社会经济地位患者病因特异生存更差。
  • 需针对增加可及性和差异来改善宫颈癌结局。

研究设计与样本

  • 使用加州癌症登记处数据,纳入2004至2014年FIGO IB2-IVA期宫颈癌患者4783例。
  • 收集肿瘤、人口学和社会经济因素,采用多因素逻辑回归分析BT使用的预测因素,采用Cox比例风险模型分析BT与外照射推量对病因特异生存和总生存的影响。

主要发现

  • FIGO分期分布为IB2期11%、II期32%、III期54%、IVA期3%。
  • 45%患者接受BT,18%接受外照射推量,37%未接受推量。
  • 与IB2期相比,II期和III期更可能接受BT(p=0.002和p=0.0168)。
  • 随着年龄增长,BT使用减少。
  • 多因素分析显示BT影响病因特异生存(HR 1.16,p=0.0330)和总生存(HR 1.14,p=0.0333)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The treatment for locally advanced cervical cancer is external beam radiation (EBRT), concurrent chemotherapy, and brachytherapy (BT). We investigated demographic and socioeconomic factors that influence trends in BT utilization and disparities in survival. METHODS: Using the California Cancer Registry, cervical cancer patients FIGO IB2-IVA from 2004 to 2014 were identified. We collected tumor, demographic and socioeconomic (SES) factors. We used multivariable logistic regression analysis to determine predictors of use of BT. Using Cox proportional hazards, we examined the impact of BT vs EBRT boost on cause specific (CSS) and overall survival (OS). RESULTS: We identified 4783 patients with FIGO stage 11% IB2; 32% II, 54% III, 3% IVA. Nearly half (45%) of patients were treated with BT, 18% were treated with a EBRT boost, and 37% had no boost. Stage II and III were more likely to be treated with BT (p = 0.002 and p = 0.0168) vs Stage IB2. As patients aged, the use of BT decreased. Using multivariate analysis, BT impacted CCS (HR 1.16, p = 0.0330) and OS (HR 1.14, p = 0.0333). Worse CSS was observed for black patients (p = 0.0002), low SES (p = 0.0263), stage III and IVA (p < 0.0001. Black patients, low and middle SES had worse OS, (p = 0.0003). CONCLUSIONS: The utilization of BT in locally advanced cervical cancer was low at 45%, with a decrease in CSS and OS. Black patients and those in low SES had worse CSS. As we strive for outcome improvement in cervical cancer, we need to target increasing access and disparities for quality and value.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Mayadev J, Klapheke A, Yashar C, et al. Underutilization of brachytherapy and disparities in survival for patients with cervical cancer in California. Gynecol Oncol. 2018. PMID: 29709291. doi:10.1016/j.ygyno.2018.04.563

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。